Small molecule antagonism of oxysterol-induced Epstein–Barr virus induced gene 2 (EBI2) activation

Tau Benned-Jensen\(^a\), Christian M. Madsen\(^a\), Kristine N. Arfelt\(^a\), Christian Smethurst\(^b\), Andy Blanchard\(^b\), Robert Jepras\(^b\), Mette M. Rosenkilde\(^a,\ast\)

\(^a\)Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark
\(^b\)GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom

**Article history:**
Received 11 February 2013
Received in revised form 14 February 2013
Accepted 14 February 2013

**Keywords:**
7TM receptors
EBI2
Oxysterols
Antagonism
MAP kinase activation
Epstein–Barr virus

**ABSTRACT**

The Epstein–Barr virus induced gene 2 (EBI2) was recently identified as the first oxysterol-activated 7TM receptor. EBI2 is essential for B cell trafficking within lymphoid tissues and thus the humoral immune response in general. Here we characterize the antagonism of the non-peptide molecule GSK682735A, which blocks oxysterol-induced G-protein activation, \(\beta\)-arrestin recruitment and B-cell chemotaxis. We furthermore demonstrate that activation triggers pertussis toxin-sensitive MAP kinase phosphorylation, which is also inhibited by GSK682735A. Thus, EBI2 signalling in B cells mediates key phenotypic functions via signalling pathways amenable to manipulation providing additional therapeutic options for inhibiting EBI2 activity.

\(\ast\) Corresponding author. Tel.: + 45 30604608; fax: + 45 35327610.
E-mail address: rosenkilde@sund.ku.dk (M.M. Rosenkilde).

1. Introduction

The Epstein–Barr virus induced gene 2 (EBI2 also known as GPR183) is a G protein-coupled seven-transmembrane (7TM) receptor that is predominantly expressed in B and T cells [1,2]. It regulates the trafficking of B cells within lymphoid tissues and is highly important for the generation of humoral immune responses [3,4]. EBI2 remained orphan for years; however, two independent studies recently showed that this receptor is activated by oxysterols, most potently by \(7\alpha,25\text{-dihydroxycholesterol} (7\alpha,25\text{-OHC}) [5,6]\). Binding of oxysterols to EBI2 induce \(\text{G}\)xi activation, \(\beta\)-arrestin recruitment and ultimately migration of EBI2-expressing B and T cells. Thus, EBI2 functions as a chemo-attractant receptor. Interestingly, the main oxysterol generating cells within the lymphoid tissue were recently shown to be of stromal origin and these are required for efficient T cell-dependent plasma cell responses [7]. Moreover, we [8,9] and others [10] identified residues critical for oxysterol binding to EBI2 showing that the main anchor points are found in TM-II, -III, -VI and ECL2 of which several are located in the minor binding pocket [11].

The expression of EBI2 has been found to be dysregulated in several types of B cell malignancies and is thus reduced in e.g. diffuse large B-cell lymphomas [12] and chronic lymphocytic leukemia [13] and increased in post-transplantation lymphoproliferative disorders (PTLDs) [14]. EBI2 is also highly expressed in EBV-transformed lymphoblastoid B cells which phenotypically resemble PTLDs [15].

We recently showed that increased expression of EBI2 potentiates antibody-induced proliferation in B cells [16]. Thus, in malignancies where EBI2 expression is increased, this receptor may contribute to pathogenesis possibly by potentiating B cell proliferation. In such cases, blocking EBI2 activity could serve as a target for pharmacotherapy. Furthermore, this could also be envisioned to apply in autoimmune-mediated diseases such as lupus and rheumatoid arthritis. Finally, the up-regulation of EBI2 upon EBV infection may function to position B cells in specific lymphoid zones in order to increase overall viral survival. Blocking EBI2 activity may therefore serve as a novel route to treat EBV infection as no EBV-specific drugs are currently available. Of note, EBI2 is expressed both in the latent and lytic infection stages as opposed to e.g. the EBV-encoded 7TM receptor BILF1 or other EBV genes [1,17]. The desire to develop tool compounds for modulating EBI2 activity is exemplified well by an ongoing uHTS screen at the Sanford-Burnham Center for Chemical Genomics where a range of compounds able to antagonize \(7\alpha,25\text{-OHC}\)-mediated \(\beta\)-arrestin recruitment has been identified in a primary screen (PubChem BioAssay ID: 651636).

**Abbreviations:** \(7\alpha,25\text{-OH}\), \(7\alpha,25\text{-dihydroxycholesterol}; 7TM, seven-transmembrane; EBI2, Epstein–Barr virus induced gene 2; PTLD, post transplantation lymphoproliferative disorder; OE, over-expression; pTx, pertussis toxin.
Simultaneous to the deorphanization of EBI2, we provided a characterization of a non-peptide inverse agonist (coined GSK682753A) that suppressed the apparent constitutive activity of the receptor [16]. Here we investigate the antagonistic properties of this compound and find that it potently suppresses 7α,25-OHCh-mediated GaI activation, β-arrestin recruitment and chemotaxis of primary B cells ex vivo. Furthermore, for the first time we demonstrate that 7α,25-OHCh-induced activation of EBI2 triggers pertussis toxin (ptx)-sensitive MAP kinase phosphorylation which also is suppressed by GSK682753A.

2. Materials and methods

2.1. Ligands

7α,25-OHCh was purchased from Avanti Polar Lipids and GSK682753A was synthesized in-house at GlaxoSmithKline. Both were dissolved in DMSO; final DMSO concentration was 0.1%.

2.2. Transfection and cell culture

CHO cells were grown in RPMI1640 containing 10% FBS, 2 mM glutamine, 180 u/ml penicillin and 45 μg/ml streptomycin (PenStrep) at 5% CO₂ and 37 °C. Stably transfected CHO FLP-In cells were grown in the same medium also containing 600 μg/ml Hygromycin. The CHO-K1 EA-arrestin cell line was grown in F-12 HAM medium containing 10% FBS, PenStrep and 250 μg/ml Hygromycin.

2.3. Receptor constructs

All constructs contained an N-terminal M1-FLAG tag to facilitate immunostaining. This does not affect the ligand-induced activity of EBI2. Mutations were generated using the Quick Change protocol.

2.4. Membrane preparation

Membrane preparations of CHO FLP-In cells stably expressing M1-EBI2 wt or pcDNA5 were generated as previously described [9].

2.5. GTPγS binding assay

Measurement of GTPγS binding to CHO FLP-In M1-EBI2 wt or pcDNA5 membranes upon 7α,25-OHCh agonism or GSK682753A antagonism was performed as described previously [9]. Briefly, 10 μg of membrane preparation was incubated 30 min in the presence of ligands at various concentrations and [35S] GTPγS at 1 nM. Wheat-germ agglutinin-coupled SPA beads were subsequently added (2.8 mg/mL) followed by 30 min incubation. After centrifugation (1500 rpm, 5 min) the amount of GTPγS binding was measured using a TopCounter. Nonspecific binding was determined by adding unlabeled GTPγS at 40 μM.

2.6. β-Arrestin recruitment

Recruitment of β-arrestin was measured using the PathHunter β-arrestin assay (DiscoveRx). cDNA encoding M1-EBI2 wt was fused to the PK1-tag and the small fragment of β-galactosidase and cloned into pcDNA3.1 + . Assays were performed in a CHO-K1 EA-arrestin cell line stably expressing β-arrestin coupled to the β-gal large fragment. Cells were seeded out at 20,000/well in 96-well plates and transfected the following day with 50 ng DNA using FuGENE6 reagent (0.15 μL/well). 48 h after transfection, cells were stimulated with varying concentrations of 7α,25-OHCh and/or GSK682753A for 90 min. β-Arrestin recruitment was detected as β-gal activity 60 min after addition of chemiluminescent substrate.

2.7. Chemotaxis

B cells were isolated from wt and EBI2-overexpressing C57BL/6 mice as previously described [16]. Chemotaxis was measured using 96-well ChemoTx plates with 5 μm pores. Various concentrations of 7α,25-OHCh and/or GSK682753A were applied to the lower chemotaxis chambers and 200,000 B cells subsequently added to the filter. The plates were incubated for 5 h at 37 °C and the number of cells migrated into the lower chambers detected using the CellTiterGlo dye and a TopCounter.

2.8. MAP kinase phosphorylation

CHO cells stably expressing EBI2 or pcDNA5 were seeded out in 12-well plates. The cells were serum starved overnight and incubated with GSK682753A and/or 7α,25-OHCh at varying concentrations (for EBI2 and pcDNA) for 10 min. Subsequently, the cells were washed twice, lysed in lysis buffer (100 mM Tris, 4% SDS, 20% glycerol) and centrifuged for 5 min at 1500 rpm. 15–20 μg protein was loaded on Bis–Tris 10% NuPAGE gels and run for 1.5 h at 140 V followed by blotting onto PVDF membranes for 1.5 h at 30 V. The membrane was blocked in TBST (1 × TBS with 0.1% Tween20) containing 5% BSA followed by incubation with rabbit anti-phospho ERK or anti-phospho p38 IgG antibody (1:1000). Following washing, the membrane was incubated in blocking buffer containing goat anti-rabbit-IgG HRP-conjugated antibody (1:10,000) and developed using Supersignal West Pico substrate (Pierce). The amount of phosphorylation was measured using a FluorChem H2A camera. The membrane was subsequently stripped using Pierce stripping buffer (Pierce) and the procedure was then repeated with rabbit anti-ERK or anti-p38 IgG antibody to detect total ERK or p38 levels.

3. Results

3.1. GSK682753A antagonizes 7α,25-OHCh-induced EBI2 activation

GSK682753A is a piperidine-based non-peptide molecule identified in a compound library screen as an EBI2 inverse agonist [16] (Fig. 1A). To examine the putative antagonistic properties of GSK682753A we initially sought to determine whether GSK682753A was able to block oxysterol-induced activation of EBI2 at the level of G protein activation. In agreement with previous studies [5,6], 7α,25-OHCh, the most potent EBI2-activating oxysterol, induced GTPγS binding to membranes from CHO cells stably expressing EBI2 wt (but not to pcDNA5 controls) when present (Fig. 1B; [7α,25-OHCh] = 1 nM, [GSK682753A] = 0). However, presence of GSK682753A dose-dependently blocked EBI2 activity with an IC₅₀ of 0.2 μM demonstrating that GSK682753A indeed functions as an antagonist (Fig. 1B). To determine whether this antagonism is competitive or non-competitive, we investigated the effect of three different GSK682753A concentrations on 7α,25-OHCh dose–response curves (Fig. 2A). As the presence of GSK682753A resulted in a rightward shift in 7α,25-OHCh potency curve with only limited effect on the efficacy, this suggest that GSK682753A functions as a competitive antagonist. This is further corroborated by Schild plot analysis showing a linear relationship between the concentration of GSK682753A and the log(dr-1) value (Fig. 2B; slope: 1.4). The Kᵦᵣ, estimated from the x-axis interception, is 64 nM.

To characterize the antagonism of GSK682753A further downstream and in a G protein-independent pathway, we measured β-arrestin recruitment in transiently transfected CHO cells. 7α,25-OHCh induced β-arrestin recruitment with an EC₅₀ value of 0.2 μM in accordance with earlier studies [5,6] (Fig. 3A). GSK682753A also inhibited β-arrestin recruitment but with a slightly higher potency than in the GTPγS binding assay (IC₅₀ value of 40 nM; [7α,25-OHCh] = 1 μM) (Fig. 3B). We have previously shown that the Phe at position
III:08/3.32 in TM-III (F111) is crucial for the efficacy of GSK682753A as an inverse agonist [16]. To determine whether this also is the case for GSK682753A as an antagonist we mutated F111 to Ala and Tyr. Whereas F111 is not required for 7α,25-OHC binding (Fig. 3A) it is essential for the antagonism of GSK682753A as Ala but not Tyr substitution of F111 profoundly reduced the potency of GSK682753A (Fig. 3B).

Finally, as 7α,25-OHC functions as a chemoattractant [5,6], we examined whether GSK682753A is able to block 7α,25-OHC-induced chemotaxis of B cells in vitro. We used B cells from both wt and EBI2-overexpressing (OE) mice to assess the importance of EBI2 expression level. 7α,25-OHC induced chemotaxis that peaked at 1 nM in both cases (Fig. 3C). EBI2-OE cells tended to migrate more efficiently than their wt counterparts, which is in line with data from EBI2-deficient and heterozygous B cells [5]. In agreement with the results from the GTPsyS and β-arrestin recruitment assays, GSK682753A dose-dependently blocked the B cell migration (Fig. 3D; shown for EBI2-OE cells only). Interestingly, the potency (7 PM) was much higher compared to the other assays. This could however be due to a generally higher sensitivity for ligand-modulation of EBI2 in this assay as also the potency of the endogenous agonist 7α,25-OHC was increased. Thus, the EC50 of the agonist was 0.1 nM in the chemotaxis assay compared to 1 and 100 nM the GTPyS (Fig. 2A) and β-arrestin recruitment (Fig. 3A) assays, respectively.

3.2. 7α,25-OHC induces MAP kinase activation

It has previously been shown that 7α,25-OHC activates the Gαi pathway [5,6]. However, whether 7α,25-OHC induces MAP kinase activation upon binding to EBI2 remains to be elucidated. To examine this, we measured ERK1/2 and p38 phosphorylation in CHO cells stably expressing EBI2 in the presence of 7α,25-OHC. As seen in Fig. 4A, 7α,25-OHC induced a dose-dependent activation of ERK1/2 with an EC50 value of 3 nM. This activation was inhibited by ptx indicating ERK1/2 phosphorylation to be dependent of Gαi pathway activity. In line with this, GSK682753A also inhibited ERK1/2 activation with an IC50 of 8 nM (Fig. 4B). Finally, we also examined whether EBI2 activation results in activation of the p38 MAP kinase. As seen in Fig. 4C, like ERK, p38 was dose-dependently activated by 7α,25-OHC in a ptx-sensitive manner. Thus, oxysterol binding to EBI2 leads to activation of at least two MAP kinases.

4. Discussion

Much has been learned about the biology and pharmacology of EBI2 in the past 2 years. Thus, both the endogenous agonist [5,6], the cellular producers of this agonist [7] and the molecular pharmacology of 7α,25-OHC, the most potent agonist, [9,10] have all been characterized within this period. In addition, just prior to the deorphanization, we presented a non-peptide compound, GSK682753A, which inhibited the apparent constitutive activity of EBI2 [16]. Here, we have investigated the antagonistic properties of this molecule showing that it blocks oxysterol-induced G protein activation (Figs 1 and 2), β-arrestin recruitment (Fig. 3A and B), B cell chemotaxis (Fig. 3C and D) and ERK activation (Fig. 4). Compared to the in vitro assays, the potency measured in the ex vivo chemotaxis assay was much higher. At present we cannot explain this difference. However, we have recently characterized a series of CR8 antagonists and also observed higher potencies in chemotaxis assays compared to IP3 accumulation [18], and in line with the concomitant higher potency of 7α,25-OHC it is possible that an increase in assay sensitivity could be a contributing factor.
Collectively, our results indicate that GSK682753A functions as a competitive antagonist and binds to the receptor in the same region as 7α,25-OHC. First, we observe linearity in the Chplot plot analysis (Fig. 2B). Second, GSK682753A is highly dependent on F111 at position III:08/3.32 in TM-III (Fig. 3B). Although this is not the case for 7α,25-OHC (Fig. 3A), it has recently been shown that the TM-III residues V112 at position III:09/3.33 (just next to F111) and V116 at III:13/3.37 are crucial for agonist binding [9,10]. Third, the two ligands bind in the same region. Interestingly, the primary uHTS screen at Sanford-Burnham Center for Chemical Genomics identified 2946 compounds out of 364,168 tested that were able to suppress 7α,25-OHC-induced β-arrestin recruitment at 5 μM by more than 50% (PubChem BioAssay ID: 651638). Of note, the most efficacious of the active compounds are very similar in structure to GSK682753A. For instance, the best compound (CID: 5804570) also has two chlorine-substituted benzene-rings at each extremity, an enone moiety and a centrally-located nitrogen-containing ring (in this case a piperazine). Thus, it seems that these structural traits are important for efficacious inhibition of EBI2 activity. It should be noted that we first characterized GSK682753A as an inverse agonist [16]. However, new data indicate that a part of the constitutive activity of EBI2 may be a result of oxygen contamination in the medium [9]. Thus, the inverse agonism of GSK682753A might have been antagonistic. It is possible that EBI2 is constitutively active; however, presently we cannot assess the magnitude of this (if any) with the tools available.

As EBI2 is highly important for generation of an efficient T cell-dependent humoral immune response [5–7] it may be that aberrant expression or other dysregulation of this receptor contributes in B cell pathologies. In line with this, EBI2 expression is down-regulated in diffuse large B-cell lymphomas [12] and chronic lymphocytic leukemia [13] but up-regulated in PTLDs [14]. Interestingly, PTLDs are highly associated with Epstein–Barr virus (EBV) seropositivity which agrees well with the finding that EBV infection of B cells in vitro results in transformation of these into highly proliferative lymphoblastoids [19]. In both cases, the expression of EBI2 is highly upregulated suggesting that this receptor could play a role in pathogenesis [2,15] putatively in combination with BIF1 [20]. This is also indicated by the observation that the proliferation of B cells over-expressing EBI2 is higher than wt counterparts [16]. Importantly, the proliferation could be blocked by GSK682753A suggesting that targeting EBI2 could be therapeutically beneficial. This may not only be limited to malignant diseases but may also extend to EBV-associated benign conditions such as mononucleosis for which no treatment is currently available.

**Funding**

The work presented here was supported by financial grants from the NovoNordisk Foundation, The Danish Council for Independent Research | Medical Sciences, and the Aase and Einar Danielsen Foundation. None of the funding sources were involved in the present work.

**Acknowledgements**

We thank Inger Smith Simonsen for excellent technical assistance.

**References**

[1] Rosenkilde M.M., Benned-Jensen T., Andersen H., Holst P.J., Kledal T.N., Littauhart H.R. et al. (2006) Molecular pharmacological phenotyping of EBI2. An orphan seven-transmembrane receptor with constitutive activity. J. Biol. Chem. 281, 13199–13208.

[2] Birkenbach M., Jøsseten K., Yalamanchili R., Lenoir G., Kieff E. (1993) Epstein–Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J. Virol. 67, 2209–2220.

[3] Pereira J.P., Kelly L.M., Xu Y., Oyster J.G. (2009) EBI2 mediates B cell segregation between the outer and centre follicle. Nature 460, 1122–1126.

[4] Gatto D., Paus D., Basten A., Mackay C.R., Bink R. (2009) Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. Immunity 31, 259–269.

[5] Liu C., Yang X.V., Wu J., Kuei C., Mani N.S., Zhang L. et al. (2011) Oxygenol direct B-cell migration through EBI2. Nature 475, 519–523.

[6] Hannedouche S., Zhang J., Yi T., Shen W., Nguyen D., Pereira J.P. et al. (2011) Oxygenol direct immune cell migration via EBI2. Nature 475, 524–527.

[7] Yi T., Wang X., Kelly L.M., An J., Xu Y., Sailer A.W. et al. (2012) Oxygenol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. Immunity 37, 533–544.

[8] Benned-Jensen T., Rosenkilde M.M. (2008) Structural motifs of importance for the constitutive activity of the orphan 7TM receptor EBI2: analysis of receptor activation in the absence of an agonist. Mol. Pharmacol. 74, 1008–1021.

[9] Benned-Jensen T., Norn C., Laurent S., Madsen C., Larsen H.M., Arfelt K.N. et al. (2012) Molecular characterization of oxygenol binding to the Epstein–Barr virus-induced gene 2 (GPR183). J. Biol. Chem. 287, 35470–35483.

[10] Zhang L., Shih A.Y., Yang X.V., Kuo C., Wu J., Deng X. et al. (2012) Identification of structural motifs critical for EBI2 function and homology modeling of ligand docking site. Mol. Pharmacol. 82, 1094–1103.

[11] Rosenkilde M.M., Benned-Jensen T., Frimurer T.M., Schwartz T.W. (2010) The minor binding pocket: a major player in 7TM receptor activation. Trends Pharmacol. Sci. 31, 567–574.

[12] Alizadeh A.A., Eisen M.B., Davis R.E., Ma C.,LOSSOS I.S., Rosenwald A. et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511.

[13] Aalton Y., El-Rifa W., Vilpo L., Ollila J., Nagy B., Vihinen M. et al. (2001) Distinct gene expression profiling in chronic lymphocytic leukemia with 11q23 deletion. Leukemia 15, 1721–1728.

[14] Craig D., Johnson L.R., Harvey S.A., Nalesnik M.A., Luo J.H., Bhattacharya S.D.
et al. (2007) Gene expression profiling of Epstein–Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders. Diagn. Mol. Pathol. 16, 158–168.

[15] Cahir-McFarland E.D., Carter K., Rosenwald A., Giltnane J.M., Henrickson S.E., Staudt L.M. et al. (2004) Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein–Barr virus latency III-infected cells. J. Virol. 78, 4108–4119.

[16] Benned-Jensen T., Smethurst C., Holst P.J., Page K.R., Sauls H., Sivertsen B. et al. (2011) Ligand modulation of the Epstein–Barr virus-induced seven-transmembrane receptor EBI2: identification of a potent and efficacious inverse agonist. J. Biol. Chem. 286, 28202–28202.

[17] Paulsen S.J., Rosenkilde M.M., Eugen-Olsen J., Kledal T.N. (2005) Epstein–Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 79, 536–546.

[18] Rummel P., Arfelt K., Baumann L., Jenkins T., Thiele S., Luttichau H. et al. (2012) Molecular requirements for inhibition of the chemokine receptor CCR8 – probe-dependent allosteric interactions. Br. J. Pharmacol. 167, 1206–1217.

[19] Young L.S., Rickinson A.B. (2004) Epstein–Barr virus: 40 years on. Nat. Rev. Cancer 4, 757–768.

[20] Lyngaa R., Norregaard K., Kristensen M., Kubale V., Rosenkilde M.M., Kledal T.N. (2010) Cell transformation mediated by the Epstein–Barr virus G protein-coupled receptor BILF1 is dependent on constitutive signaling. Oncogene 29, 4388–4398.